GeoVax Labs (GOVX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellectual property protection related to its vector platform for expressing a tumor associated antigen, TAA, in virus-like particles, VLPs, from a recombinant Modified Vaccinia Ankara, MVA, viral vector, further demonstrating the GeoVax technical expertise.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX:
- WHO determines mpox upsurge still constitutes public health emergency
- GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology
- GeoVax Labs Reports Improved Earnings and Strategic Progress
- GeoVax Labs reports Q3 EPS (91c), consensus ($1.48)
- Pinterest, Cisco upgraded: Wall Street’s top analyst calls
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue